- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01522872
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Monterey, California, United States, 93940
- Pacific Cancer Care
-
-
Florida
-
Tampa, Florida, United States, 33612
- Moffitt Cancer Center
-
-
Maine
-
Scarborough, Maine, United States, 04074
- Maine Center for Cancer Medicine
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, United States, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Mississippi
-
Southaven, Mississippi, United States, 38671
- The West Clinic
-
-
New York
-
Albany, New York, United States, 12208
- New York Oncology Hematology
-
Hudson, New York, United States, 12534
- New York Oncology Hematology
-
-
Tennessee
-
Memphis, Tennessee, United States, 38120
- The West Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- At least 18 years of age.
- Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's IRB/Ethics Committee.
- Relapsed/refractory multiple myeloma for which no standard therapy options are anticipated to result in a durable remission.
- Receipt of at least two prior therapies as indicated by protocol
- Subjects with measurable disease
- ECOG performance status of less than or equal to 2
- Acceptable liver function
- Acceptable renal function
- Acceptable hematologic status
For Part A, B, C subjects: Women of childbearing potential must have a negative serum pregnancy test and women and men subjects must agree to use effective means of contraception with their partner as indicated by protocol For Part D subjects: a negative serum pregnancy test is required within 10- 14 days prior to initiating with pomalidomide, AND a negative serum pregnancy test within 24 hours of starting pomalidomide and must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control at least 28 days before she starts taking pomalidomide.
Women of childbearing potential must enroll into and follow all requirements of the POMALYST REMS program, which includes adhering to the scheduled pregnancy testing.
Men must agree to use a latex or synthetic condom during sexual contact with women of child bearing potential even if they have had a vasectomy.
All subjects must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure, or when a female patient misses her period or if there is any abnormality in her menstrual bleeding.
- Subjects must adhere to the study visit schedule and other protocol requirements and receive outpatient therapy and laboratory monitoring at the institute that administers the study drug.
Exclusion Criteria
Subjects who meet any of the following exclusion criteria are not eligible to be enrolled in this study:
- POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes.)
- Waldenstrom's macroglobulinemia
- Localized radiation therapy to only measurable disease site(s) within 2 weeks of treatment
- New York Heart Association (NYHA) Class III or IV, cardiac disease, myocardial infarction within 6 months prior to Day 1, or unstable arrhythmia
- Significant neuropathy (Grade 3 or 4, or Grade 2 with pain) at the time of enrollment or within 14 days before enrollment
- Symptomatic brain metastases (unless previously treated and well controlled for a period of ≥ 3 months)
- Severe chronic obstructive pulmonary disease with hypoxemia or in the opinion of the investigator any physiological state leading to hypoxemia
- Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without complete recovery
- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy within 14 days prior to the first dose
- Previously treated malignancies, except for adequately treated non-melanoma skin cancer (basal cell or squamous cell), in situ cancer, or other cancer from which the subject has been disease-free for at least 5 years
- Subjects who participated in an investigational drug or device study within 2 weeks prior to study entry
- Known or suspected active infection with HIV, hepatitis A, hepatitis B, or hepatitis C
- Subjects who have exhibited allergic reactions to a similar structural compound, biological agent, or formulation similar to TH-302, bortezomib (for subjects enrolled in Part C only), pomalidomide (Part D), dexamethasone or pimonidazole
- Females who are pregnant or breast-feeding
- Concomitant psychiatric disease or medical condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
- Unwillingness or inability to comply with the study protocol for any reason
- Previous cytotoxic therapies for multiple myeloma within 3 weeks prior to study entry (2 weeks for biologic, novel therapy or corticosteroids)
- Subjects who have been on hormone replacement less than 2 months (subjects on hormone replacement for at least 2 months will not be excluded provided the HRT regimen remains unchanged during the conduct of the study).
- Prior peripheral stem cell transplant within 12 weeks of the start of study
- Epilepsy or other convulsive disorder requiring active management
- Prior therapy with a pomalidomide-containing regimen
- Subjects on strong inducers or strong inhibitors of cytochrome P450 CYP3A4 or CYP1A2
- Any other medical condition that in opinion of investigator would place patient at increased risk for toxicity during pomalidomide treatment (i.e. history of recurrent or serious thromboembolic events)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Monotherapy TH-302 Dose Escalation
|
|
EXPERIMENTAL: TH-302 and Dexamethasone Dose Expansion
|
|
EXPERIMENTAL: TH-302 Dose Escalation and Dexamethasone with Bortezomib
|
|
EXPERIMENTAL: TH-302 Dose Escalation and Dexamethasone with Pomalidomide
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with adverse events (AEs)
Time Frame: Up to 30 days after last dose
|
Up to 30 days after last dose
|
Type of adverse events(AEs)
Time Frame: Up to 30 days after last dose
|
Up to 30 days after last dose
|
Severity of adverse events(AEs)
Time Frame: Up to 30 days after last dose
|
Up to 30 days after last dose
|
dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of TH-302 and dexamethasone with or without bortezomib or pomalidomide
Time Frame: 2 years
|
2 years
|
recommended Phase 2 dose for TH-302 and dexamethasone with or without bortezomib or pomalidomide
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall Survival (OS)
Time Frame: Up to 12 weeks post treatment
|
Up to 12 weeks post treatment
|
Progression-free survival(PFS)
Time Frame: Up to 12 weeks post treatment
|
Up to 12 weeks post treatment
|
Duration of Response (DOR)
Time Frame: Up to 12 weeks post treatment
|
Up to 12 weeks post treatment
|
relationship between hypoxia within the bone marrow of subjects with relapsed/refractory multiple myeloma and response to TH-302 and dexamethasone with or without bortezomib or pomalidomide using markers of hypoxia
Time Frame: Up to 12 weeks post treatment
|
Up to 12 weeks post treatment
|
Maximum plasma concentration of TH-302 and bortezomib
Time Frame: Cycle 1 Day 1 predose and up to 24 hours postdose
|
Cycle 1 Day 1 predose and up to 24 hours postdose
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protease Inhibitors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Dexamethasone
- Dexamethasone acetate
- BB 1101
- Pomalidomide
- Bortezomib
- Phosphoramide Mustards
Other Study ID Numbers
- TH-CR-408
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on TH-302
-
Threshold PharmaceuticalsCompletedAcute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | High-risk Myelodysplastic Syndrome | Advanced MyelofibrosisUnited States
-
Threshold PharmaceuticalsTerminatedMetastatic MelanomaUnited States, Canada
-
Sarcoma Alliance for Research through CollaborationThreshold PharmaceuticalsNo longer availableSoft Tissue Sarcoma
-
Threshold PharmaceuticalsUnknown
-
Threshold PharmaceuticalsCompletedHypoxia | TumorsUnited States
-
Seoul National University HospitalThreshold PharmaceuticalsCompletedBiliary Tract CancerKorea, Republic of
-
Herbert Hurwitz, MDGlaxoSmithKline; National Comprehensive Cancer Network; Threshold PharmaceuticalsCompleted
-
Merck KGaA, Darmstadt, GermanyThreshold PharmaceuticalsCompleted
-
Threshold PharmaceuticalsCompletedSoft Tissue SarcomaUnited States
-
Threshold PharmaceuticalsUnknownGastrointestinal Stromal Tumors | Advanced Renal Cell Carcinoma | Pancreatic Neuroendocrine TumorsUnited States